diaDexus, Inc. was founded in 1997 and is based in South San Francisco, California. diaDexus, Inc., a biotechnology company, engages in the discovery, development, and commercialization of in vitro diagnostic products to address the medical needs in the cardiovascular field. The company develops The PLAC Test, a blood test to aid in assessing risk for coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis. Its product measures lipoprotein-associated phospholipase A2 (Lp-PLA2), which is a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. The company’s PLAC Test is available as an ELISA assay that runs on an automated micropate system, as well as in the form of immunotarbidimetric technology that runs on common clinical chemistry analyzers used in clinical reference laboratories, hospitals, and physician office laboratories.

NeuroNova wants to recharge neurons. The biopharmaceutical company is engaged in the research and development of therapies to help regenerate central nervous system cells in patients with Alzheimer's disease, Parkinson's disease, and other disorders. Its research focuses on developing drugs that will stimulate endogenous stem and progenitor cells to restore damaged areas of the brain. The company has two drug candidates nearing clinical development in addition to other compounds in the discovery and pre-clinical phases. NeuroNova was founded in 1998 and is financed by Swedish venture capital companies HealthCap, Scandinavian Life Science Venture, and Investor Growth Capital.

Ranbaxy Laboratories Limited company is India's largest drug manufacturer, as well as a top global generics producer. Anti-infectives amoxycillin and ciprofloxacin, and cardio drug simvastatin are among Ranbaxy's top sellers; all come in several administration forms. The company also addresses gastrointestinal, musculoskeletal, and central nervous system disorders, as well as diabetes, pain, allergies, and HIV/AIDS. Its R&D focus includes new forms of existing drugs and metabolic disease treatments. The company also has a groundbreaking anti-malarial candidate in late-phase trials. Japanese drugmaker Daiichi Sankyo owns a controlling stake in Ranbaxy.

Neurocrine Biosciences, Inc. was founded in 1992 and is based in San Diego, California. Neurocrine Biosciences, Inc. engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company develops drugs for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine related diseases and disorders. Its products in clinical development comprise Elagolix, a Phase II product for Endometriosis; CRF1 Antagonist, a phase II product for mood disorders; CRF2 Peptide Agonist, a phase II drug for Cardiovascular related diseases; CRF1 Antagonist, a Phase I product for treating Mood Disorders and Irritable Bowel Syndrome; and Elagolix, a Phase I product for treating Benign Prostatic Hyperplasia and Uterine Fibroids. The company's research programs include Vesicular Monoamine Transporter 2 Inhibitor for movement disorders and schizophrenia; Glucose Dependent Insulin Secretagogues for type II diabetes; Antiepileptic drugs for epilepsy and bipolar disorder; and GnRH Antagonists for hormone dependent diseases and oncology. It has strategic alliances with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan.

A. Nelson & Co. is Europe's oldest and the UK's largest manufacturer of homeopathic medicines and other natural healthcare products. Its homeopathic creams, ointments, sprays, and tablets treat a range of health problems from common colds to skin conditions. Its formulated remedies include Travella for travel sickness, Teetha for teething discomfort, Coldenza for cold and flu symptoms, Noctura for insomnia, and Pollenna for hay fever. The company is the manufacturer of Bach floral remedies, including the popular Rescue Remedy. Nelson distributes its products worldwide and operates specialized manufacturing labs in the UK. The company is owned by the Wilson family.

Network Biosystems develops high throughput DNA sequencing systems with applications in the personalized medicine, forensics, drug discovery, and security arenas. The company blends nanotechnology and mircrofluidics to achieve its DNA analysis. Its sequencing systems were conceived at MIT's Whitehead Institute. The company is in the developmental stage and is pursuing a variety of commercial applications including manufacturing a rugged portable STR analysis and identification in the forensics field and on site screening of large numbers for use by homeland security.

Rowett Research Services (RRS) will supply the technology, thanks to its research parent, the Rowett Institute. It will even throw in marketing services and project management. All RRS needs are companies interested in commercializing new ideas and products. Its primary focuses are nutrition issues and outpatient health care studies, such as antimicrobial agents and antioxidants. Founded in 1988, RRS works with public and private partners in the pharmaceutical, biotechnology, food, and agricultural industries to bring the research underway at the Rowett Institute to the marketplace.

TapImmune Inc. is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s lead product, the TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. The Company’s vaccine has shown effective restoration of TAP which restores and augments the marker (antigen) presentation and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works as an adjuvant or ‘accelerant’ to enhance targeted vaccines against infectious diseases. Including TAP in the studied Smallpox Vaccine showed potency was increased by 100-1000 times. The company is currently developing AdhTAP for the commencement of toxicology studies leading to the initiation of Phase I clinical trials. The global vaccine market is expected to grow from $13 billion in 2007 to $21 billion in 2010.

NeuTec wants to make visiting the hospital an experience that lessens patient dangers. The biopharmaceutical company identifies and compares antibodies produced by patients who recover from infections (acquired in hospitals) to those produced by patients who die. Then, using its FabTec technology, it develops genetically recombinant antibodies, or "grabs," to treat patients with life-threatening infections. The company's two leading candidates, Mycograb, which targets a fungus in the mouth and skin, and Aurograb, which targets bacterial infections, are in clinical trials in the UK. Mycograb also is in clinical trials in the US.

Sirtris Pharmaceuticals can help keep you healthy in your golden years. The biopharmaceutical company focuses on developing drugs for treating ailments of aging. Its trial drug for the treatment of Type 2 Diabetes, which is associated with obesity, provides health benefits similar to calorie restriction without a change in diet. Founded in 2004, the company owns or licenses more than 150 patent applications for sirtuins, a class of enzymes. The activation of sirtuins helps reduce weight gain, as well improve glucose levels and insulin sensitivity. Sirtris filed an IPO in 2007, but was then acquired by GlaxoSmithKline (GSK) the following year.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.